![Jonathan Aballi, President and Chief Executive Officer. [NASDAQ XGN] at Exagen](https://exagen.wpenginepowered.com/wp-content/uploads/2022/11/John-A-Headshot.png){kind=small}
Biodesix
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Colorado, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
919 W Dillon Rd, Louisville, Colorado, 8...Phone Number
(303) 417-0500Website
www.biodesix.comRevenue
$96.1 MillionStock Symbol
BDSXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
4
1
1
About Biodesix
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions.Explore more
Biodesix Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Biodesix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Biodesix launches new products
Click to see if Biodesix had a recent Job posting/layoffs
Check if Biodesix has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Biodesix recently announced quarterly report
Check out if Biodesix is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Biodesix
Funding: Get notified immidiatlly once Biodesix has new funding data
Biodesix, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Biodesix
Find more new buyers
Compare Similar Companies to Biodesix
Compare insights from companies similar to Biodesix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$60.1M
51-200
Private
$82M
2006
DV
Daniel VummagoniCorporate Development Senior VP & Chief Financial Officer
Company Profile Activity
Activity Insights
Biodesix is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Biodesix is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Biodesix.
Biodesix financials insights
Gather financial insights about Biodesix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Series C
$7.1M
2011
Series D
$20M
2015
Series E
$38M
2016
Series F
$22M
2018
Debt
$23M
2020
Debt
$2M
Stock Offering
$72M
2022
Stock Offering
$16.3M
Stock Offering
$50M
Biodesix Tech Stack
A closer look at the technologies used by Biodesix
See more technologies
Most Recent Scoops
Person-Based
Earnings, Forecasting, Finance
Person-Based
Medical Research
Person-Based
Award, Sales
Person-Based
Medical Research
Person-Based
Medical Research, Healthcare Technology, Patient Experience
Biodesix News & Media
Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy
Includes real-world clinical data from Biodesix researchers and independent Healthcare Professionals Includes real-world clinical data from Biodesix researchers and independent Healthcare ProfessionalsBiodesix Announces First Quarter 2026 Results and Highlights
Delivered $25.6 million in revenue representing 42% growth in Q1 2026;Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026
LOUISVILLE, Colo., April 20, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarter ended March 31, 2026 after the close of trading on Monday, May 4. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.Biodesix Recognized as a Top Workplace for Third Consecutive Year
Employee-Driven, Prestigious National Recognition for the Consistently High-Performing Biodesix Culture Employee-Driven, Prestigious National Recognition for the Consistently High-Performing Biodesix Culture
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Biodesix
Sign Up For FreeTo access detailed company insights
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathwa... Read More
